# An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

> **NCT07469683** · PHASE2 · RECRUITING · sponsor: **Yonsei University** · enrollment: 78 (estimated)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Neoplasms
- Malignant Neoplasms
- Malignant Neoplasm of Kidney, Except Renal Pelvis

## Interventions

- **DRUG:** SLC-3010 + Axitinib
- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT07469683
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2029-10
- **Final completion:** 2029-10
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07469683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07469683, "An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07469683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*